Elanco Animal Health Incorporated (ELAN) Stock: Price, Forecast & Analyst Target
Elanco Animal Health Incorporated (ELAN) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $26.70 (+3.29%), as of the Nov 18, 2026 trading session; market cap $13.4B.
Educational signal · not a buy or sell recommendation · How to read this
Elanco Animal Health Incorporated · ELAN · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-13: Elanco manufactures animal medicines and health products sold through veterinary, distribution and farm channels, with demand divided almost evenly between pets and production animals. The case depends on whether recent revenue and gross-profit strength can become durable earnings and cash generation while the debt load remains far larger than available cash.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Elanco Animal Health (ELAN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $1.14B (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 1.54 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 36 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $26.70 | |
| Change on the day | +3.29% | |
| 52-week range | $19.40–$27.98 | |
| Market capitalisation | $13.4B | — |
| Price / earnings (trailing) | 20.15 | |
| Shares traded on the day | 5.78M | |
| Beta (volatility vs the S&P 500) | 1.72 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Elanco Animal Health (ELAN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Elanco Animal Health (ELAN), and what does it report?
Short answer · as of
Elanco sells preventive products, vaccines and treatments for pets, alongside medicines, vaccines and nutritional products used by cattle, poultry, swine and aquaculture producers.
Research dated 2026-09-13.
Seresto, Galliprant, Rumensin and Baytril represent different demand streams rather than variations on a single drug franchise.
The healthcare taxonomy suggests a conventional specialty-drug manufacturer, but Elanco's reported sales measure a blend of pet care and livestock production demand. Pet Health and Farm Animal contribute similar amounts, while veterinary clinics, distributors and producers form the route to market.
What do the latest results show for Elanco Animal Health (ELAN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1.14B.
Research dated 2026-09-13.
Recent revenue held near the strongest level in the available quarterly series, while gross profit improved again. Operating profit nevertheless fell sharply from the prior period as selling and administrative expense rose, showing that stronger sales and gross profit did not flow cleanly through the cost base.
Reported revenue and earnings have exceeded expectations throughout the recent reporting sequence. Management also says favorable foreign exchange contributed to its revenue outlook and that much of this benefit had already been realized, so currency should be separated from product-demand progress.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1.14B | -$34M | -$0.07 (diluted) |
| Q4 FY2025 | $1.14B | -$276M | -$0.56 (diluted) |
| Q1 FY2026 | $1.37B | $57M | $0.11 (diluted) |
| Q2 FY2026 | $1.37B | $54M | $0.11 (diluted) |
What are the financial strengths and risks for Elanco Animal Health (ELAN)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Elanco has recently produced positive operating cash flow after an earlier period of cash use, and the latest period delivered the strongest cash generation in the available sequence while capital spending remained contained. Cash also recovered from the prior period, providing near-term flexibility.
The constraint is leverage: debt substantially exceeds cash and short-term investments, leaving the company in a sizable net-debt position. Profitability is not yet dependable either; annual net results have swung between profit and loss, while trailing margins and returns remain negative despite positive operating profitability.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.54 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-2.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Elanco Animal Health (ELAN)?
Short answer · as of
Current published price targets run low $24.00 · high $30.00 · consensus $26.67 · median $26.00 against a quoted price of $26.70 (as of Nov 18, 2026).
Research dated 2026-09-13.
The scheduled earnings release should be judged on whether revenue stays near its recent level, gross-profit strength persists without another rise in selling and administrative expense, and operating cash flow continues to cover capital spending. Cash retention matters because debt reduction cannot rely on the balance sheet alone.
Management's outlook includes an exchange-rate benefit concentrated earlier in the reporting period, which raises the importance of underlying demand from pet owners, veterinarians and livestock producers. Longer-range analyst estimates assume continued revenue and earnings expansion, making sustained operating execution more informative than another isolated expectation beat.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Elanco Animal Health compare with its peers?
Short answer
Elanco Animal Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Elanco differs from a pet-only animal-health company because its sales base is split between companion-animal care and farm-animal production. Pet products address parasites, vaccines and chronic conditions, while the farm portfolio reaches cattle, poultry, swine and aquaculture through medicines, vaccines and nutritional tools.
That mix spreads demand across veterinary care and agricultural production, but it also means consolidated performance reflects distinct purchasing cycles and customer economics. The reported segment balance is therefore more informative than the broad specialty-drug classification.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $28.96 Nov 18, 2026 | $6.02B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $13.99 Nov 18, 2026 | $2.43B | 70 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $42.23 Nov 18, 2026 | $49.3B | 57 5-pillar Nov 18, 2026 | |
| $4.69 Nov 18, 2026 | $2.33B | 47 5-pillar Nov 18, 2026 | |
| Elanco Animal Health (ELAN) — this page | $26.70 | $13.4B | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $24.00 – $30.00
- Consensus target
- $26.67
- Median target
- $26.00
Consensus record · Captured .
Measured against a quoted price of $26.70 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 30, 2026
- Transactions
- 46
- Identified insiders
- 10
- Purchases
- 5
- Sales
- 1
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ELAN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.06% | $13.23M | Added +612.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Elanco Animal Health (ELAN)?
Common Questions About ELAN (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Seresto and Galliprant fit Elanco's Pet Health business?
Seresto serves preventive parasite control, while Galliprant treats canine osteoarthritis pain. Together they show that Pet Health spans recurring prevention and therapeutic care rather than relying on a single treatment category.
Why do Rumensin and Baytril make Elanco more than a pet-health company?
Those brands sit within a farm-animal portfolio serving livestock producers with medicines and health-management products. Farm Animal contributes sales comparable with Pet Health, making agricultural demand a core part of Elanco's economics.
Why does favorable foreign exchange matter to Elanco's current outlook?
Management included a favorable currency contribution in its revenue outlook and indicated that much of the benefit had already occurred. Subsequent performance therefore needs to distinguish exchange-rate support from demand for Elanco's products.
How does Elanco sell to veterinary clinics and livestock producers?
Elanco distributes through independent distributors and veterinary clinics while also serving cattle, dairy, swine, poultry and aquaculture operations. The channel structure connects branded pet treatments with farm products used across animal production.
What is the ELAN stock price today?
The last price recorded for Elanco Animal Health Incorporated (ELAN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ELAN price target?
The analyst consensus price target for Elanco Animal Health Incorporated (ELAN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 22 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold ELAN
Funds in our ETF coverage that list ELAN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Dimensional - US Small Cap Value ETF (DFSV) | 0.65% |